Search clinical trials for: Mircera

Total 197 results

Hoffmann-La Roche

Completed

A Study of MIRCERA in Participants With Chronic Kidney Disease Stage 3-4 and Not on Dialysis

Anemia

Sweden
Samsung Medical Center

Unknown

Phase IV Study to Evaluate the Efficacy and Safety of Mircera in PD

PD

Korea, Republic of
Akebia Therapeutics

Completed

Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects

Anemia Associated With Chronic Kidney Disease (CKD)

United States
Hoffmann-La Roche

Completed

A Study of Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) for the Treatment of Chronic Renal Anemia in Participants With Diabetic Nephropathy

Anemia

India
Hoffmann-La Roche

Completed

An Observational, Prospective, Safety Study of Mircera (Monopegylated Epoetin Beta) in Clinical Practice

Kidney Disease, Chronic

Korea, Republic of
Hoffmann-La Roche

Completed

An Observational Study of Mircera (Methoxy Polyethylene Glycol-epoetin Beta) in Anemic Patients With Chronic Kidney Disease (NORM)

Anemia

Pakistan
Hoffmann-La Roche

Completed

Observational Study of MIRCERA in Users of Self-Application and Multidose Systems

Renal Anemia of Chronic Kidney Disease

Germany
PT Kalbe Genexine Biologics
Novotech (Australia) Pty Limited

Completed

A Study of Efepoetin Alfa in Treating Anaemia Associated With Chronic Kidney Diseases Patient

Anaemia Associated With Chronic Kidney Disease

Taiwan, Australia, Korea, Republic of, Thailand, Malaysia, Philippines, Indonesia
Hoffmann-La Roche

Completed

Ascertain the Optimal Starting Dose of Mircera Given Subcutaneously for Maintenance Treatment of Anemia in Pediatric Patients With Chronic Kidney Disease on Dialysis or Not Yet on Dialysis.

Renal Insufficiency, Chronic | Anemia

United States, Spain, France, Hungary, Italy, Lithuania, Poland
Hoffmann-La Roche

Completed

A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis.

Anemia

United States, Canada, United Kingdom, Mexico, Poland
Hoffmann-La Roche

Completed

A Study of Mircera (C.E.R.A.) in Patients With Pre-Dialysis Chronic Renal Anemia

Anemia

Egypt
Hoffmann-La Roche

Completed

An Observational Study to Evaluate the Effectiveness of Mircera Treatment for Renal Anemia in Pre-dialysis Participants With Chronic Kideny Disease (CKD)

Kidney Disease, Chronic

Slovenia
Hoffmann-La Roche

Completed

A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Participants With Chronic Kidney Disease Not on Dialysis

Renal Anemia, Chronic

Italy, Spain, Hong Kong, Taiwan, Hungary, Korea, Republic of, Australia, Canada, France, Germany, Greece, Belgium, Thailand, Poland, Russian Federation, Israel
Hoffmann-La Roche

Completed

An Observational Study of Methoxy Polyethylene Glycol-epoetin Beta in Participants With a Kidney Transplant

Anemia, Kidney Transplantation

Germany
Medtronic

Active, not recruiting

Micra Transcatheter Pacing System Post-Approval Registry

Bradycardia

United States, France, Italy, Poland, United Kingdom, Germany, Spain, Switzerland, Belgium, Portugal, Japan, Saudi Arabia, Israel, Netherlands, Greece, Canada, New Zealand, Hungary, Sweden, Czechia, Denmark, Norway, Iceland, Kuwait
Hoffmann-La Roche

Terminated

A Study Comparing Mircera and Epoetin Alfa for the Treatment of Anemia in Dialysis Patients With Chronic Kidney Disease.

Anemia

United States
Hoffmann-La Roche

Completed

A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.

Anemia

Belgium, Italy, Poland, Spain, Hong Kong, Canada, France, Greece, Czech Republic, Austria, Estonia, Hungary, Australia, Germany, Finland
Hoffmann-La Roche

Completed

An Observational Study of Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) in Stage V Chronic Kidney Disease Participants on Hemodialysis

Anemia

South Africa
Hoffmann-La Roche

Completed

A Study of Subcutaneous Mircera for the Maintenance Treatment of Participants With Chronic Renal Anemia

Anemia

Belgium
Hoffmann-La Roche

Completed

A Study of Subcutaneous (sc) Mircera in Dialysis Patients With Chronic Renal Anemia.

Anemia

Italy, Spain, United States, Germany
Hoffmann-La Roche

Completed

A Study of Intravenous (iv) Mircera in Hemodialysis Patients With Chronic Renal Anemia

Anemia

United States
Hoffmann-La Roche

Completed

A Study of Two-Weekly Intravenous Mircera for the Treatment of Dialysis Patients With Chronic Renal Anemia Not Receiving ESA Therapy.

Anemia

India
Hoffmann-La Roche

Completed

Observational Study of Methoxy Polyethylene Glycol Epoetin Beta Daily Use in Participants on Peritoneal Dialysis

Renal Impairment | Renal Anemia of Chronic Kidney Disease

Germany
Hoffmann-La Roche

Completed

An Observational Study of Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) in Chronic Kidney Disease Participants on Dialysis (IMPACT)

Chronic Kidney Diseases

Israel
Hoffmann-La Roche

Completed

A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.

Anemia

Belgium, Italy, Spain, Canada, Denmark, France, Austria, Switzerland, Australia, Sweden, Finland, Germany
Hoffmann-La Roche

Completed

A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.

Anemia

Belgium, Spain, United States, Sweden, Denmark, Taiwan, France, Italy, United Kingdom, New Zealand, South Africa, Hungary, Thailand, Mexico, Poland, Czech Republic, Puerto Rico, Finland, Brazil, Germany, Panama
Hoffmann-La Roche

Completed

A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients

Anemia

Italy, Spain, Australia, France, Canada, Germany, United Kingdom, Belgium, Austria, Switzerland, Netherlands, Denmark, Finland, Portugal
Hoffmann-La Roche

Completed

An Observational Study of Mircera (Methoxy Polyethylene Glycol-epoetin Beta) in Patients With Renal Anemia

Anemia

Germany
Genexine, Inc.

Completed

Study to Evaluate the Efficacy and Safety of GX-E2 in the Anemic Patients Diagnosed With Chronic Kidney Disease (CKD)

Anemia | Chronic Kidney Disease

Korea, Republic of
Hoffmann-La Roche

Completed

A Study of Intravenous Mircera in Dialysis Patients With Chronic Renal Disease and Anemia.

Anemia

Russian Federation
Hoffmann-La Roche

Completed

A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.

Anemia

Germany
Hoffmann-La Roche

Completed

A Study of Intravenous Mircera for the Correction of Anemia in Dialysis Patients.

Anemia

Korea, Republic of
Hoffmann-La Roche

Completed

STABIL Study: National Study With Mircera for Maintenance of Hemoglobin Level in Dialysis Patients

Anemia

Czech Republic
Hoffmann-La Roche

Terminated

A Study of Subcutaneous Mircera for the Treatment of Anemia in Pre-Dialysis Participants With Chronic Kidney Disease.

Anemia

Estonia, Latvia, Finland, Norway
Duke University

Withdrawn

Micra AV Tracking During Exercise Testing

Heart Block AV

United States
Biocad

Completed

Comparative Study of the Efficacy and Safety of BCD-131 and Mircera in Treatment of Anemia in CKD Patients on Dialysis

Anemia

Russian Federation, Belarus
University Hospital, Basel, Switzerland

Completed

Hemoglobin Kinetics in Response to Mircera® in Patients With Acute Myocardial Infarction (BEATSTEMIPi)

Acute Myocardial Infarction

Switzerland
Hoffmann-La Roche

Terminated

A Study of Subcutaneous Mircera, Versus no Erythropoiesis-Stimulating Agent (ESA) Therapy, in the Treatment of Anemia in Patients With Chronic Kidney Disease After Kidney Transplant

Anemia

France, United Kingdom, Germany, Spain, Belgium, Italy
Hoffmann-La Roche

Completed

A Study Comparing Mircera and Epoetin Beta for the Treatment of Anemia in Dialysis Patients With Chronic Kidney Disease.

Anemia

China, Hong Kong
Hoffmann-La Roche

Completed

A Study of Intravenous Mircera in Participants With Chronic Renal Anemia Who Are on Dialysis

Anemia

Hungary
Hoffmann-La Roche

Completed

A Study of The Effect of Altitude on Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) Dose Requirements in Participants With Chronic Renal Anemia in Pre-Dialysis or Dialysis (ALTITUD)

Anemia, Kidney Disease, Chronic

Mexico
Hoffmann-La Roche

Completed

A Study of Once Monthly Subcutaneous Mircera in Patients With Chronic Renal Anemia Not on Dialysis

Anemia

Korea, Republic of
Hoffmann-La Roche

Completed

A Study of Mircera in Renal Anemia Among Filipino Chronic Kidney Disease Patients

Anemia

Philippines
Hoffmann-La Roche

Completed

A Study to Assess Hemoglobin Level Depending on the Comorbidity Index in Chronic Kidney Disease (CKD) Participants Not in Dialysis Treated With Methoxy Polyethylene Glycol-Epoetin Beta (COMETE)

Renal Anemia of Chronic Kidney Disease

France
Hoffmann-La Roche

Completed

A Study of Once Monthly Intravenous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.

Anemia

India
Hoffmann-La Roche

Terminated

A Study for Monthly Methoxy Polyethylene Glycol-Epoetin Beta Treatment in Patients With Chronic Renal Anaemia

Anemia

Indonesia
Hoffmann-La Roche

Completed

LATINO Study: A Study of Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.

Anemia

Mexico, Colombia, Argentina, Venezuela, Brazil, Uruguay, Ecuador, Peru, Chile
Hoffmann-La Roche

Completed

A Study of Subcutaneous Mircera in Participants With Chronic Kidney Disease Not Treated With ESA or on Dialysis (MERCUR)

Anemia

Germany
Hoffmann-La Roche

Terminated

A Study of Once-Monthly Subcutaneous Mircera for the Treatment of Chronic Renal Anemia in Pre-Dialysis Patients Not Currently Treated With ESA.

Anemia

Costa Rica, Guatemala, Argentina, Brazil, Panama, Chile, Colombia, Ecuador, Peru, Venezuela
Hoffmann-La Roche

Withdrawn

A Study of Once-Monthly Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia.

Anemia

Denmark

3

Subscribe